[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11202102057SA - Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate - Google Patents

Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate

Info

Publication number
SG11202102057SA
SG11202102057SA SG11202102057SA SG11202102057SA SG11202102057SA SG 11202102057S A SG11202102057S A SG 11202102057SA SG 11202102057S A SG11202102057S A SG 11202102057SA SG 11202102057S A SG11202102057S A SG 11202102057SA SG 11202102057S A SG11202102057S A SG 11202102057SA
Authority
SG
Singapore
Prior art keywords
annulene
oxyphenyl
fluoropropyl
pyrrolidin
dichlorophenyl
Prior art date
Application number
SG11202102057SA
Other languages
English (en)
Inventor
Alain Rabion
Michel Tabart
Christian Wehrey
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11202102057SA publication Critical patent/SG11202102057SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/1616Coordination complexes, e.g. organometallic complexes, immobilised on an inorganic support, e.g. ship-in-a-bottle type catalysts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/06Oxalic acid
    • C07C55/07Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255Tartaric acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Health & Medical Sciences (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202102057SA 2018-09-07 2019-09-06 Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate SG11202102057SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306177 2018-09-07
PCT/EP2019/073827 WO2020049153A1 (en) 2018-09-07 2019-09-06 Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate

Publications (1)

Publication Number Publication Date
SG11202102057SA true SG11202102057SA (en) 2021-03-30

Family

ID=63637829

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202102057SA SG11202102057SA (en) 2018-09-07 2019-09-06 Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate
SG11202102059YA SG11202102059YA (en) 2018-09-07 2019-09-06 Salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate and preparation process thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202102059YA SG11202102059YA (en) 2018-09-07 2019-09-06 Salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate and preparation process thereof

Country Status (19)

Country Link
US (2) US11713296B2 (el)
EP (2) EP3847156B1 (el)
JP (2) JP7398436B2 (el)
KR (2) KR20210057031A (el)
CN (2) CN112638869A (el)
AR (2) AR116300A1 (el)
AU (2) AU2019335542A1 (el)
BR (2) BR112021003061A2 (el)
CA (2) CA3111466A1 (el)
CY (2) CY1125418T1 (el)
DK (2) DK3847156T3 (el)
ES (2) ES2923412T3 (el)
HU (2) HUE059362T2 (el)
IL (2) IL281191B (el)
MX (2) MX2021002666A (el)
SG (2) SG11202102057SA (el)
TW (2) TWI803692B (el)
WO (2) WO2020049153A1 (el)
ZA (2) ZA202101006B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
AU2019335542A1 (en) 2018-09-07 2021-04-01 Sanofi Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-(4-((3s)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxyphenyl)-8,9-dihydro-7H-benzo(7)annulene-2-carboxylate
BR112022009705A2 (pt) 2019-12-09 2022-08-09 Sanofi Sa Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica
WO2022001971A1 (zh) 2020-06-28 2022-01-06 南京明德新药研发有限公司 并环吲唑类化合物
CA3196092A1 (en) 2020-10-19 2022-04-28 Patrick Bernardelli Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
EP4228758B1 (en) 2020-10-19 2024-07-24 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
EP4458821A1 (en) 2021-12-28 2024-11-06 Shenzhen Vybio Pharmaceutical Technology Co., Ltd. Salt form and crystal form of tetrahydrocyclohepta indazole compound
WO2023187086A1 (en) 2022-03-31 2023-10-05 Sanofi Amorphous solid form of amcenestrant
WO2023198904A1 (en) * 2022-04-15 2023-10-19 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof
WO2023198901A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted 4-amino-4-oxo-but-2-enyl derivatives, processes for their preparation and therapeutic uses thereof
WO2023198903A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine and n‑propyl-azetidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198905A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated vinyl-n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198879A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015579A1 (en) 1991-03-08 1992-09-17 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
DE19833786A1 (de) 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
EP1229036B1 (en) 2001-01-24 2005-01-12 CHIESI FARMACEUTICI S.p.A. 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
EE200400061A (et) 2001-08-11 2004-04-15 Bristol-Myers Squibb Pharma Company Trifenüületüleeni derivaadid kui selektiivsed östrogeeniretseptori modulaatorid ja neid sisaldavad ravimkoostised
DK1501819T3 (da) 2002-04-24 2011-01-10 Merck Sharp & Dohme Østrogenreceptormodulatorer
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
BRPI0512623A (pt) 2004-06-25 2008-03-25 Janssen Phamaceutica N V sal quaternário antagonista de ccr2
US7429681B2 (en) 2005-06-14 2008-09-30 Baylor University Combretastatin analogs with tubulin binding activity
US8127618B1 (en) 2007-05-18 2012-03-06 Pacesetter, Inc. Implantable micro-electromechanical system sensor
EP2048126A1 (de) 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
WO2009101634A2 (en) 2008-02-13 2009-08-20 Lupin Limited A novel process for the preparation of eszopiclone
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2012068284A2 (en) 2010-11-16 2012-05-24 Baylor University Efficient method for preparing functionalized benzosuberenes
AU2011347718B2 (en) 2010-12-24 2016-06-23 Msd Oss B.V. N-substituted azetidine derivatives
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
JP2015504049A (ja) 2011-12-30 2015-02-05 センタウルス・バイオファーマ・カンパニー・リミテッドCentaurus Biopharma Co.,Ltd. 新規アリールアルケン誘導体およびその選択的エストロゲン受容体調整剤における使用
CN110368497B (zh) 2013-08-14 2022-05-13 诺华股份有限公司 用于治疗癌症的组合疗法
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN105916501A (zh) 2013-12-06 2016-08-31 豪夫迈·罗氏有限公司 用于治疗局部晚期或转移性雌激素受体阳性乳腺癌的雌激素受体调节剂
TWI699363B (zh) 2014-12-18 2020-07-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
KR102676705B1 (ko) 2015-04-29 2024-06-18 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
CN106924210A (zh) 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
MX2018009908A (es) 2016-02-15 2018-09-07 Sanofi Sa Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrogenos.
JP6946430B2 (ja) 2016-11-17 2021-10-06 サノフイSanofi 新規の置換n−(3−フルオロプロピル)−ピロリジン化合物、それを製造するための方法、およびその治療的使用
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
AU2019335542A1 (en) 2018-09-07 2021-04-01 Sanofi Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-(4-((3s)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxyphenyl)-8,9-dihydro-7H-benzo(7)annulene-2-carboxylate
TW202038951A (zh) 2018-11-16 2020-11-01 美商亞闊股份有限公司 用於治療癌症之醫藥組合
AU2020268762A1 (en) 2019-05-09 2021-12-02 Sanofi 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients
CA3148592A1 (en) * 2019-07-22 2021-01-28 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
US20220389006A1 (en) * 2019-11-04 2022-12-08 Recurium Ip Holdings, Llc Salts and forms of an estrogen receptor modulator
BR112022009705A2 (pt) * 2019-12-09 2022-08-09 Sanofi Sa Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica

Also Published As

Publication number Publication date
IL281191B (en) 2022-07-01
TWI803692B (zh) 2023-06-01
SG11202102059YA (en) 2021-03-30
HUE059362T2 (hu) 2022-11-28
CA3111466A1 (en) 2020-03-12
CN112638869A (zh) 2021-04-09
JP2021536468A (ja) 2021-12-27
ES2924738T3 (es) 2022-10-10
KR20210057031A (ko) 2021-05-20
KR20210057032A (ko) 2021-05-20
MX2021002665A (es) 2021-07-16
US20210188772A1 (en) 2021-06-24
EP3847157B1 (en) 2022-05-18
EP3847157A1 (en) 2021-07-14
MX2021002666A (es) 2021-07-16
HUE059527T2 (hu) 2022-11-28
IL281196B2 (en) 2023-02-01
ZA202101006B (en) 2022-08-31
WO2020049150A1 (en) 2020-03-12
AU2019335542A1 (en) 2021-04-01
US20210188771A1 (en) 2021-06-24
IL281191A (en) 2021-04-29
IL281196B (en) 2022-10-01
AR116300A1 (es) 2021-04-21
TW202026280A (zh) 2020-07-16
BR112021003440A2 (pt) 2021-05-18
US11713296B2 (en) 2023-08-01
IL281196A (en) 2021-04-29
EP3847156B1 (en) 2022-05-04
AR116299A1 (es) 2021-04-21
WO2020049153A1 (en) 2020-03-12
JP7398436B2 (ja) 2023-12-14
ES2923412T3 (es) 2022-09-27
EP3847156A1 (en) 2021-07-14
JP7413363B2 (ja) 2024-01-15
CA3111359A1 (en) 2020-03-12
CY1125486T1 (el) 2024-09-20
CN112638870A (zh) 2021-04-09
CY1125418T1 (el) 2024-09-20
TW202024032A (zh) 2020-07-01
ZA202101079B (en) 2022-09-28
JP2021536471A (ja) 2021-12-27
DK3847156T3 (da) 2022-07-25
BR112021003061A2 (pt) 2021-05-11
AU2019336532A1 (en) 2021-04-01
DK3847157T3 (da) 2022-08-08

Similar Documents

Publication Publication Date Title
ZA202101006B (en) Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate
IL272166A (en) A combination containing palbociclib and 6-(4,2-dichlorophenyl)-5-[4-[(S3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-H7-benzo [7] Anolin-2 carboxylic acid and its use in cancer treatment
AU2019382117A1 (en) Process for the preparation of (S)-nicotin from myosmine
EP3459925A4 (en) PROCESS FOR THE PREPARATION OF 2-HYDROXYL-4- (BENZYLOXY 2,3-DISUBSTITUTED) -5-SUBSTITUTED BENZALDEHYDE DERIVATIVE
PL3653617T3 (pl) Sposób otrzymywania (s)-nikotyny z miozminy
WO2007013096A8 (en) Improved process for the preparation of 2r, 3s-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol (voriconazole)
EP3953339C0 (en) PROCESS FOR PREPARING 1-DEOXY-1-METHYLAMINO-D-GLUCITOL-2-(3,5-DICHLOROPHENYL)-6-BENZOXAZOLE CARBOXYLATE
IL287805A (en) 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene -2-carboxylic for use in metastatic or advanced breast cancer patients
WO2016159576A3 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
EP3835427A4 (en) PROCESS FOR GENERATION OF 3,5-DIHYDROXY-4-METHOXYBENZYL ALCOHOL FROM PLANKTON
IL246596A0 (en) ((r)-3-((3s, 4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and prodrugs for the treatment of psychiatric disorders
EP3233824A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
EP3233079A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
EP4069228A4 (en) PROCESS FOR PREPARING 2-(4-CHLORPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUORACETAMIDE
IL268358B (en) Process for preparing methyl-4-[((4,5-dihydro-3-methoxy-4-methyl-5-oxo-h1- 1,2,4-triazol-1-yl)carbonyl)sulfamoyl]-5-methylthiophene- 3-carboxylate
EP3793976A4 (en) INDOLE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF
MA56071A (fr) Procédés de préparation de 3-bromo-1-(3-chloropyridine-2-yl)-1h-pyrazole-5-carboxylate d'éthyle
AU2018904171A0 (en) Process for preparing 2-substituted 3',4'-polyhydroxystilbene compounds
IL291634A (en) Process for the preparation of 1,1'-disulfandylbis(4-fluoro-2-methyl-5-nitrobenzene)
TWI799535B (zh) 從二烷基二硫化物製備二硫代碳酸s,s’-二烷酯之方法
AU2017904453A0 (en) Process for preparing 2-substituted 3',4'-polyhydroxystilbene compounds
IL259332A (en) Process for the synthesis of intermediates useful for preparing 1,3,4-triazine derivatives
PL3153022T3 (pl) N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid
IL200178A0 (en) Process for the preparation of (r) -5- (2-aminoethyl) -1- (6, 8-difluorochroman-3-yl) -1, 3-dihydroimidazole-2-thione